Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis

Diabetes Technology and Therapeutics

Volumn 17, Issue 1, 2015, Pages 35-42

  Sun, Feng ^a,b,c   Chai, Sanbao ^d   Yu, Kai ^e   Quan, Xiaochi ^a   Yang, Zhirong ^a   Wu, Shanshan ^a   Zhang, Yuan ^a   Ji, Linong ^f   Wang, J Un ^d   Shi, Luwen ^c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHIHEZI UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^f PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; INCRETIN; PEPTIDE; ZP10A PEPTIDE;

ARTICLE; DATA BASE; DIARRHEA; DRUG DOSE REGIMEN; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT INDICATION; AGONISTS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; NAUSEA; VOMITING;

DIABETES MELLITUS, TYPE 2; DIARRHEA; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; MIDDLE AGED; NAUSEA; PEPTIDES; RECEPTORS, GLUCAGON; VOMITING;

EID: 84920814490     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0188     Document Type: Article

References (44)

1. Whiting DR, Guariguata L, Weil C, et al.: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321.
2. Levetan C: Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007;23:945-952.
3. Pratley RE: Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 2008;10:171.
4. Hansen KB, Knop FK, Holst JJ, et al.: Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract 2009;63:1154-1160.
5. Drucker DJ, Nauck MA: The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
6. Tzefos M, Harris K, Brackett A: Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother 2012;46:68-78.
7. Zinman B, Schmidt WE, Moses A, et al.: Achieving a clinically relevant composite outcome of an HbA1c of an HbA1c of 7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012, 14, 77-82
8. Amori RE, Lau J, Pittas AG.Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis.JAMA2007;298:194-206
9. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. JAMA 2007;298:194-206.
10. Norris SL, Lee N, Thakurta S, et al.: Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26:837-846.
11. Shyangdan DS, Royle P, Clar C, et al.: Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;(10):CD006423.
12. Li WX, Gou JF, Tian JH, et al.: Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Curr Ther Res Clin Exp 2010;71: 211-238.
13. Montanya E, Sesti G: A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009;31:2472-2488.
14. Jadad AR, Moore RA, Carroll D, et al.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
15. Keus F, Wetterslev J, Gluud C, et al.: Robustness assessments are needed to reduce bias in meta-analyses that include zeroevent randomized trials. Am J Gastroenterol 2009;104: 546-551.
16. Fleiss JL: The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-145.
17. Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23: 3105-3124.
18. Ades AE, Sculpher M, Sutton A, et al.: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19.
19. Salanti G, Marinho V, Higgins JP: A case study of multipletreatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009;62:857-864.
20. Spiegelhalter DJ, Best NG, Carlin BP, et al.: Bayesian measures of model complexity and fit. J R Stat Soc B 2002;64:583-639.
21. Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-171.
22. Ebert EC: Gastrointestinal complications of diabetes mellitus. Dis Mon 2005;51:620-663.
23. Sogabe M, Okahisa T, Tsujigami K, et al.: Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control. J Gastroenterol 2005;40:583-590.
24. Quan C, Talley NJ, Jones MP, et al.: Gain and loss of gastrointestinal symptoms in diabetes mellitus: associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up. Am J Gastroenterol 2008;103:2023-2030.
25. Merian F, Malagelada JR: Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995;7:713-723.
26. Rayner CK, Samsom M, Jones KL, et al.: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001;24:371-381.
27. Fineman MS, Bicsak TA, Shen LZ, et al.: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377.
28. Bytzer P, Talley NJ, Jones MP, et al.: Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther 2001;15:137-142.
29. Ishii M, Nakamura T, Kasai F, et al.: Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994;17:901-903.
30. Shyangdan DS, Royle PL, Clar C, et al.: Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10:20.
31. Macconell L, Brown C, Gurney K, et al.: Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012;5:29-41.
32. Cai L, Cai Y, Lu ZJ, et al.: The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 2012;37: 386-398.
33. Nauck MA, Ratner RE, Kapitza C, et al.: Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32:1237-1243.
34. Raz I, Fonseca V, Kipnes M, et al.: Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care 2012;35:485-487.
35. Moretto TJ, Milton DR, Ridge TD, et al.: Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2008;30:1448-1460.
36. Nauck M, Frid A, Hermansen K, et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009;32:84-90.
37. Kadowaki T, Namba M, Yamamura A, et al.: Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009;56:415-424.
38. Blevins T, Pullman J, Malloy J, et al.: DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-1310.
39. Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
40. Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
41. Pratley R, Nauck M, Bailey T, et al.: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407.
42. Buse JB, Rosenstock J, Sesti G, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
43. Buse JB, Sesti G, Schmidt WE, et al.: Switching to oncedaily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-1303.
44. Caldwell DM, Ades AE, Higgins JP: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.